Name | 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
---|---|
Synonyms |
2-{4-[(3R)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
MK-4827 (R-enantiomer) |
Description | Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent PARP1 inhibitor with IC50 of 2.4 nM. |
---|---|
Related Catalog | |
Target |
PARP-1:2.4 nM (IC50) |
In Vitro | Niraparib R-enantiomer (MK-4827 R-enantiomer) resolution of Niraparib R-enantiomer give compounds Niraparib R-enantiomer and Niraparib S-enantiomer, both showing excellent inhibition of PARP-1. Niraparib R-enantiomer has somewhat lower in vitro metabolic clearance than the Niraparib S-enantiomer in rat liver microsomes, but Niraparib S-enantiomer is more potent in cell based assays (PARylation EC50, Niraparib R-enantiomer=30 nM, Niraparib S-enantiomer=4.0 nM; BRCA1-HeLa CC50, Niraparib R-enantiomer=470, Niraparib S-enantiomer=34 nM). Given this improved potency and similar in vitro turnover in human liver microsomes (HLM Clint, Niraparib R-enantiomer=4, Niraparib S-enantiomer=3 μL/min/mgP), Niraparib S-enantiomer (Niraparib) is focused on[1]. |
References |
Molecular Formula | C19H20N4O |
---|---|
Molecular Weight | 320.38800 |
Exact Mass | 320.16400 |
PSA | 72.94000 |
LogP | 3.62050 |